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Abstract
Although the in-transit lymph node is a well-known issue in malignant melanoma, it is not documented sufficiently in breast 
cancer. In this case report an in-transit lymph node demonstrated by both PET/CT and sentinel lymph node mapping and 
diagnosed by pathology is reported.
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Introduction
Sentinel lymph node is theoretically the first lymph node to 
drain the tumor. The pathologic examination of the sentinel lymph 
node presents the further lymph nodes, thus the lymph nodal 
status of the primary tumor [1]. Previous studies have provided 
sufficient evidence that the sentinel lymph node analysis pre-
dicts the local lymphatic status of the tumor and there is a low 
risk of skip secondary lymph node invasion [2], thus recur-
rence, in the case of negative sentinel lymph node [3]. In case 
of a positive sentinel lymph node, axillary dissection has to be 
performed [4]. There are several sentinel node identification 
methods, such as blue dye and radionuclide sentinel lymph 
node imaging. These methods may be performed together and 
have low false-negative rate; however, there is a learning curve 
and experience is required [5]. Another new and not well-doc-
umented issue in sentinel lymph node imaging is the in-transit 
lymph node. In-transit or intramammary lymph node is the lymph 
node that is surrounded by the breast tissue [5, 6]. The in-transit 
lymph node as a sentinel lymph node is an unknown part of the 
procedure. This is the first case report, as far as we know, with 
intramammary in-transit lymph node scintigraphy imaging in 
combination with PET/CT imaging. 
Case Report
Case 1. A 69-year-old female patient with identified right-breast 
carcinoma was referred for F-18 FDG PET/CT for staging. The F-18 
FDG PET/CT images of the patient showed retroareolar lesion with 
significantly increased FDG uptake (2 x 1.5 cm; SUVmax = 12.6) 
and additional intramammary lymph nodes (the largest was 9 mm 
in diameter) without significant FDG uptake (Fig. 1). At the day of 
operation the sentinel lymph node imaging showed intramammary 
sentinel lymph node and during the operation the intramammary 
lymph node was excised at the border of axilla. The lymph node 
was positive for tumor and axillary dissection showed multiple 
(n = 6) positive nodes (Fig. 1). 
Case 2. The patient was 58 years old and left-breast tumor 
showed invasive carcinoma; therefore, F-18 FDG PET/CT imaging 
was performed for staging. The imaging showed left upper inner 
quadrant hypermetabolic lesion (18 x 18 mm, SUVmax = 25.6) 
and millimetric lymph node in the parenchyma with FDG uptake 
and axillary lymph node with FDG uptake (SUVmax = 3.5 and 
SUVmax = 4.2, respectively) (Fig. 2). Sentinel lymph node imag-
ing showed in-transit intramammary lymph node in early phase 
(dynamic) of the study, and in the late phase also additional 
multiple sentinel lymph nodes in axilla were observed (Fig. 2). All 
sentinel (n = 3) and axillary lymph nodes (n = 3) were positive in 
the histopathology (Fig. 2).  
Discussion
There is very limited data about the in-transit lymph nodes in 
breast cancer. There are few cases reported in the literature and 
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some review articles [5]. The in-transit lymph nodes are smaller 
diameter and closer to the lymphatic channels and the primary 
tumors. Although they are surrounded by the breast tissue and 
not exactly axillary lymph nodes, they are considered axillary lymph 
nodes in staging. They may be not recognized by the gamma cam-
era imaging or the surgeon due to close proximity (shine-through 
effect) and small volume and underestimated; however, previ-
ous reviews have demonstrated that they might be a source of 
local recurrence [5]. As in the case described by van Deurzen et 
al., in this case report we presented a patient with in-transit lymph 
node that was observed in first few second and disappeared im-
mediately after identification. Also axillary lymph nodes of the patient 
were positive as well. In the other patient, the intramammary lymph 
node was the single sentinel lymph node and the axillary lymph 
nodes were also positive. However it is problematic to determine 
the in-transit or intramammary lymph node during the scintigraphy, 
because it requires significant consideration by the physician. 
In previous studies about the in-transit lymph node in malignant 
melanoma the incidence was reported to be between 3–10% [6]. 
In 14–20% of these cases, the in-transit lymph nodes were 
found to be positive and considered one of the local recurrence 
causes in malignant melanoma [7]. Van Deurzen et al. suggested 
that these lymph nodes in breast cancer might also have major 
clinical impact [5]. 
Previous case reports have pointed out that in-transit lymph 
nodes in intramammary region might develop from the lymphatic 
emboli and be directly connected to the primary tumor [8] and 
might be one of the causes of false negative sentinel lymph node 
examinations, which can be as high as > 10% [9]. Obviously, it is dif-
ficult to localize the intramammary lymph nodes because of sur-
rounding normal breast tissue and they usually are not radioactive 
and blue. In the case of breast conserving surgery, the node may 
be missing. Scintigraphy also has disadvantage of shine-through 
effect originating from the primary tumor injection site. However, in 
our experience the intramammary lymph nodes were determined 
by the first diagnostic procedure F-18 FDG PET/CT. This is the first 
study that demonstrates the intramammary lymph nodes by both 
PET/CT and scintigraphy. 
Figure 1. The F-18 FDG PET/CT images of the first patient with lesion suspicious of in-transit lymph node, adjacent to the primary tumor in outer 
upper quadrant of the left breast in the transaxial, coronal and sagittal projection. B. Tc-99m nanocolloid sentinel lymph node dynamic images 
that show the in-transit sentinel lymph node activity adjacent to the injection site. C. Pathology images of the lymph node sections stained with 
hematoxylin and eosin in x40 and x100 magnification
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